» Articles » PMID: 38956290

A Prognostic Model for Anoikis-related Genes in Pancreatic Cancer

Overview
Journal Sci Rep
Specialty Science
Date 2024 Jul 2
PMID 38956290
Authors
Affiliations
Soon will be listed here.
Abstract

Anoikis, a distinct form of programmed cell death, is crucial for both organismal development and maintaining tissue equilibrium. Its role extends to the proliferation and progression of cancer cells. This study aimed to establish an anoikis-related prognostic model to predict the prognosis of pancreatic cancer (PC) patients. Gene expression data and patient clinical profiles were sourced from The Cancer Genome Atlas (TCGA-PAAD: Pancreatic Adenocarcinoma) and the International Cancer Genome Consortium (ICGC-PACA: Pancreatic Ductal Adenocarcinoma). Non-cancerous pancreatic tissue gene expression data were obtained from the Genotype-Tissue Expression (GTEx) project. The R package was used to construct anoikis-related PC prognostic models, which were later validated with the ICGC-PACA database. Survival analyses demonstrated a poorer prognosis for patients in the high-risk group, consistent across both TCGA-PAAD and ICGC-PACA datasets. A nomogram was designed as a predictive tool to estimate patient mortality. The study also analyzed tumor mutations and immune infiltration across various risk groups, uncovering notable differences in tumor mutation patterns and immune landscapes between high- and low-risk groups. In conclusion, this research successfully developed a prognostic model centered on anoikis-related genes, offering a novel tool for predicting the clinical trajectory of PC patients.

Citing Articles

The Oncoprotein Mucin 1 in Pancreatic Cancer Onset and Progression: Potential Clinical Implications.

Dieli R, Lioy R, Crispo F, Cascelli N, Martinelli M, Lerose R Biomolecules. 2025; 15(2).

PMID: 40001578 PMC: 11853026. DOI: 10.3390/biom15020275.


Machine learning model reveals the risk, prognosis, and drug response of histamine-related signatures in pancreatic cancer.

Li C, Yao Z, Qu C, Shao G, Liu Y, Pei X Discov Oncol. 2025; 16(1):155.

PMID: 39934551 PMC: 11813851. DOI: 10.1007/s12672-025-01910-y.

References
1.
Koshizuka K, Hanazawa T, Kikkawa N, Arai T, Okato A, Kurozumi A . Regulation of ITGA3 by the anti-tumor miR-199 family inhibits cancer cell migration and invasion in head and neck cancer. Cancer Sci. 2017; 108(8):1681-1692. PMC: 5543473. DOI: 10.1111/cas.13298. View

2.
Rizzo A, Mollica V, Tateo V, Tassinari E, Marchetti A, Rosellini M . Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. Cancer Immunol Immunother. 2023; 72(6):1381-1394. PMC: 10991194. DOI: 10.1007/s00262-023-03366-x. View

3.
Thapa B, Kc R, Uludag H . TRAIL therapy and prospective developments for cancer treatment. J Control Release. 2020; 326:335-349. DOI: 10.1016/j.jconrel.2020.07.013. View

4.
Dai Y, Zhang X, Ou Y, Zou L, Zhang D, Yang Q . Anoikis resistance--protagonists of breast cancer cells survive and metastasize after ECM detachment. Cell Commun Signal. 2023; 21(1):190. PMC: 10399053. DOI: 10.1186/s12964-023-01183-4. View

5.
Padavano J, Henkhaus R, Chen H, Skovan B, Cui H, Ignatenko N . Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways. Cancer Growth Metastasis. 2015; 8(Suppl 1):95-113. PMC: 4612127. DOI: 10.4137/CGM.S29407. View